15.55
-1.02%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guobang Pharma
Its shares trade on Shanghai under the ticker 605507.SS. It has been listed since 2 August 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.01bn and net income of CN¥820.8m. At that date it held total assets of CN¥10.98bn and shareholders' equity of CN¥8.55bn.
Guobang Pharma Ltd. engages in the research, development, manufacturing and sale of pharmaceutical products. The company is headquartered in Shaoxing, Zhejiang. The company went IPO on 2021-08-02. The firm's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Aug 2021
- Employees
- 3,706
- Website
- gbgcn.com ↗
Leadership
Pay as last reported
- Mr. Jiajun XueChairman of the Board
- Mr. Shixue LiaoPresident, Director
- Mr. Yuda GongChief Financial Officer, Secretary of the Board
- Mr. Ligao YaoVice President, Director
- Mr. Qibin LiVice President
- Ms. Fangfang LuVice President
- Mr. Dusen WangDeputy General Manager
- Mingchuan RenDirector
- Xiaoming WuDirector
- Shengjie ZhangDirector
- Yaqing ZhuDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Guobang Pharma Ltd employs 3,706 full-time employees in Shaoxing, China.
- The company produces azithromycin, clarithromycin, and roxithromycin for human health.
- Guobang Pharma offers veterinary antibiotics like florfenicol and enrofloxacin series products.
Weaknesses
- Guobang Pharma's IPO was on 2 August 2021, a relatively recent listing.
- The company focuses on pharmaceutical raw materials and intermediates in China.
- Guobang Pharma's business is limited to Shaoxing, Zhejiang, China.
Opportunities
- Guobang Pharma can expand its veterinary antibiotic products in the Chinese market.
- The company can leverage its 3,706 employees for further research and development.
- Guobang Pharma's products include azithromycin, clarithromycin, and roxithromycin for global markets.
Threats
- Guobang Pharma faces competition from other Chinese pharmaceutical companies.
- The company's reliance on Shaoxing, Zhejiang, China, may limit market access.
- Guobang Pharma's veterinary products include diclazuril and cypronamine, which face regulatory challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.